Jun 2026 (Q2 FY26) — Aug 5, 2026
Royalty Pharma Q2 FY26 — Strong Growth and Pipeline Expansion
Read the full callRoyalty Pharma (RPRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Royalty Pharma earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 674 | +16.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 19.8 | −16.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 17.9 | −44.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 15 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Second-quarter Portfolio Receipts | $740 million to $760 million | Mar 2026 | portfolio receipts are top line grew 6% in the quarter to $773 million, slightly ahead of our expectations | Achieved |
| Full-year Portfolio Receipts | $3.275 billion to $3.425 billion | Dec 2025 | We now expect portfolio receipts to be in the range of $3.4 billion to $3.5 billion up from $3.325 billion to $3.45 billion previously | Revised Up |
| Full-year interest paid | between $350 million to $360 million | Sep 2025 | We continue to expect interest paid to be around $350 million to $360 million in 2026 | On Track |
1 of Royalty Pharma plc's 30 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 27 more targets are in the full ledger.
Claimed
- Portfolio receipts grew 6% to $773 million in Q2 FY26, exceeding expectations.
- Total receipts, representing recurring cash flows, increased by 14% in Q2 FY26.
- Return on invested capital was 14.2% and return on invested equity was 20.1% for the LTM ending Q2 FY26.
- Deployed $1.1 billion of capital on royalty acquisitions year-to-date FY26, with an announced value of $1.7 billion.
- Full-year 2026 portfolio receipts guidance raised to $3.4 billion-$3.5 billion, up from $3.325 billion-$3.45 billion.
Qualified
- Milestones and other contractual receipts declined substantially in Q2 FY26 due to a prior-year one-time payment.
- The portfolio absorbed significant headwinds from Promacta's loss of exclusivity and the launch of biosimilar TYSABRI in the US.
- Milestones and other contractual receipts are expected to decrease from $128 million in 2025 to approximately $60 million in 2026.
Price
$60.27 −1.13% · −$0.69
Performance +62.8% 1Y
1Y: $37.01 on 17 Oct 2025 → $60.27. High $63.96 (4 Sept 2026), low $36.41 (28 Oct 2025).
- Previous close
- $60.96
- 52-week range
- $36.41 – $63.96
- One year
- +64.54%
Overview
- Symbol
- RPRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
14 of 15 judged targets kept · 15 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Second-quarter Portfolio Receipts | $740 million to $760 million | Mar 2026 | portfolio receipts are top line grew 6% in the quarter to $773 million, slightly ahead of our expectations | Achieved |
| Full-year Portfolio Receipts | $3.275 billion to $3.425 billion | Dec 2025 | We now expect portfolio receipts to be in the range of $3.4 billion to $3.5 billion up from $3.325 billion to $3.45 billion previously | Revised Up |
| Full-year interest paid | between $350 million to $360 million | Sep 2025 | We continue to expect interest paid to be around $350 million to $360 million in 2026 | On Track |
Claimed
- Portfolio receipts grew 6% to $773 million in Q2 FY26, exceeding expectations.
- Total receipts, representing recurring cash flows, increased by 14% in Q2 FY26.
- Return on invested capital was 14.2% and return on invested equity was 20.1% for the LTM ending Q2 FY26.
- Deployed $1.1 billion of capital on royalty acquisitions year-to-date FY26, with an announced value of $1.7 billion.
- Full-year 2026 portfolio receipts guidance raised to $3.4 billion-$3.5 billion, up from $3.325 billion-$3.45 billion.
Qualified
- Milestones and other contractual receipts declined substantially in Q2 FY26 due to a prior-year one-time payment.
- The portfolio absorbed significant headwinds from Promacta's loss of exclusivity and the launch of biosimilar TYSABRI in the US.
- Milestones and other contractual receipts are expected to decrease from $128 million in 2025 to approximately $60 million in 2026.
The full ledger
Open Royalty Pharma plc’s full ledger
A free account opens 5 company ledgers a month. All 30 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 6, 2026
Royalty Pharma Q1 FY26 — Strong Growth and Strategic Investments
Read the full callDec 2025 (Q4 FY25) — Feb 11, 2026
Royalty Pharma Q4 FY25 — Strong Growth and Capital Deployment Ahead of Schedule
Read the full callEvery analysed call
Royalty Pharma earnings calls (RPRX)
Financials
What the filings say
Net profit, year on year: −44% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 565 | 594 | 568 | 579 | 609 | 622 | 631 | 674 |
| Expenses | -170 | 232 | 34 | 369 | 182 | 234 | 68 | 541 |
| Operating profit | 735 | 362 | 534 | 210 | 427 | 388 | 563 | 133 |
| Operating margin | 130.2% | 60.9% | 94.0% | 36.3% | 70.1% | 62.4% | 89.3% | 19.8% |
| Other income | 71 | -27 | -100 | -117 | 17 | -32 | -95 | -52 |
| Interest | 67 | 66 | 65 | 69 | 80 | 94 | 94 | 94 |
| Profit before tax | 806 | 334 | 434 | 93 | 444 | 356 | 468 | 81 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | 544 | 208 | 239 | 32 | 288 | 214 | 295 | 18 |
| EPS ($ per share) | 1.22 | — | 0.55 | 0.08 | 0.67 | — | 0.67 | 0.04 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | — | 2,825 | 1,921 | 2,255 | 1,965 | 2,518 | 2,846 | 2,356 |
| Total liabilities | — | 6,308 | 6,124 | 7,267 | 7,288 | 6,298 | 7,880 | 9,906 |
| Total assets | — | 12,450 | 16,020 | 17,516 | 16,813 | 16,382 | 18,223 | 19,621 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1,618 | 1,667 | 2,035 | 2,018 | 2,144 | 2,988 | 2,769 | 2,490 |
| Cash from investing | 303 | -2,154 | -2,759 | -1,870 | -1,029 | -2,073 | -2,678 | -1,614 |
| Cash from financing | -1,379 | -1,192 | 1,487 | 385 | -945 | -2,149 | 361 | -1,186 |
| Net cash flow | 543 | -1,678 | 762 | 532 | 170 | -1,234 | 452 | -310 |
RPRX revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Financial Royalty Assets | 94% | 95% | 95% | 95% | 95% | 95% | 94% | 95% | +15.9% |
| Royalty Income Other | 6% | 5% | 5% | 5% | 5% | 5% | 6% | 5% | +27.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
105 filings between Nov 5, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$92.82M
74 sales by 5 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 29
- Award — granted as compensation
Also filed: 1 conversion, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Coyne Terrance P. | — | $38.96M | Aug 13, 2026 |
| Hite Christopher | — | $27.36M | Sep 22, 2026 |
| Lloyd George W. | — | $13.81M | Dec 18, 2025 |
| Urist Marshall | — | $12.54M | Oct 5, 2026 |
| Norden Gregory | — | $161.4K | May 14, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 4,126 | $235.6K |
| Sep 30, 2026 | Bassler Bonnie L Director | Award | 642 | $37.5K |
| Sep 28, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 4,126 | $238.8K |
| Sep 22, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 3,927 | $231.4K |
| Sep 22, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 96,073 | $5.62M |
| Aug 19, 2026 | Hite Christopher EVP & Chairman, Partnering | Gift 10b5-1 plan | 16,800 | $0 |
| Aug 18, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 100,000 | $6.00M |
| Aug 13, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,772 | $104.8K |
| Aug 13, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 9,230 | $540.8K |
| Aug 5, 2026 | Coyne Terrance P. EVP & CFO | Award | 11,002 | $0 |
| Aug 5, 2026 | Hite Christopher EVP & Chairman, Partnering | Award | 11,002 | $0 |
| Aug 5, 2026 | Legorreta Pablo G. CEO, Chairman of the Board | Award | 65,216 | $0 |
| Aug 5, 2026 | Urist Marshall EVP, Research & Investments | Award | 8,252 | $0 |
| Jul 1, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 9,099 | $508.5K |
| Jun 30, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 600 | $34.3K |
| Jun 30, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 97,446 | $5.51M |
| Jun 30, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 29,400 | $1.66M |
| Jun 30, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 2,554 | $145.8K |
| Jun 30, 2026 | Bassler Bonnie L Director | Award | 689 | $37.5K |
| Jun 24, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 9,098 | $502.1K |
| Jun 23, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 117,592 | $6.41M |
| Jun 23, 2026 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 plan | 32,408 | $1.75M |
| Jun 5, 2026 | Engelbert Catherine M. Director | Award | 4,545 | $0 |
| Jun 5, 2026 | Ho Carole Director | Award | 4,545 | $0 |
| Jun 5, 2026 | WEATHERMAN ELIZABETH H Director | Award | 4,545 | $0 |
| Jun 5, 2026 | Coric Vlad Director | Award | 4,545 | $0 |
| Jun 5, 2026 | Bassler Bonnie L Director | Award | 4,545 | $0 |
| Jun 5, 2026 | Norden Gregory Director | Award | 4,545 | $0 |
| Jun 5, 2026 | HODGSON DAVID C Director | Award | 4,545 | $0 |
| Jun 5, 2026 | LOVE TED W Director | Award | 4,545 | $0 |
| May 26, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 64,399 | $3.48M |
| May 20, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 13,684 | $721.8K |
| May 14, 2026 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 plan | 13,684 | $726.1K |
| May 14, 2026 | Norden Gregory Director | Sale 10b5-1 plan | 3,045 | $161.4K |
| May 6, 2026 | Hite Christopher EVP & Vice Chairman | Award | 24,263 | $0 |
| May 6, 2026 | Legorreta Pablo G. CEO, Chairman of the Board | Award | 143,821 | $0 |
| May 6, 2026 | Urist Marshall EVP, Research & Investments | Award | 18,197 | $0 |
| May 6, 2026 | Coyne Terrance P. EVP & CFO | Award | 24,263 | $0 |
| Apr 28, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,875 | $93.3K |
| Apr 28, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 32,916 | $1.64M |
| Apr 1, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 32,916 | $1.59M |
| Apr 1, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,875 | $90.6K |
| Mar 31, 2026 | Bassler Bonnie L Director | Award | 815 | $37.5K |
| Mar 23, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,875 | $85.4K |
| Mar 23, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 32,916 | $1.50M |
| Mar 2, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,292 | $60.3K |
| Mar 2, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 10,429 | $490.3K |
| Mar 2, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 583 | $27.4K |
| Mar 2, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 22,487 | $1.05M |
| Feb 23, 2026 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 plan | 1,875 | $85.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Royalty Pharma plc
Free account. Everything above stays public.
Write why you follow Royalty Pharma plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading